Highest-materiality recent filing
CMS final payment rate of $854 per test set (Dec 2025) for both Epi+Gen CHD (0439U) and PrecisionCHD (0440U) CPT codes.
Cardio Diagnostics regains Nasdaq minimum bid price compliance
On May 28, 2025, Nasdaq confirmed compliance after closing bid price ≥$1.00 for 10 consecutive business days (May 13-27, 2025).
Cardio Diagnostics announces 1-for-30 reverse stock split to regain Nasdaq compliance
Reverse split at 1:30, effective after close May 12; trading begins May 13 under CDIO.
Second Nasdaq letter grants 180-day extension until June 2, 2025, to meet $1.00 minimum bid price.
Received Nasdaq notice on June 3, 2024 for non-compliance with minimum bid price rule (below $1.00 for 30 consecutive days).
Cardio Diagnostics shareholders approve reverse stock split, share issuance, and board
All seven director nominees elected; each received >5.8M for, <0.4M withheld, 3.48M broker non-votes.
Cardio Diagnostics receives Nasdaq equity deficiency notice; claims cure via Yorkville conversion
Nasdaq notified CDIO on Nov 20, 2023 of non-compliance with $2.5M minimum stockholders' equity requirement.
Cardio Diagnostics receives Nasdaq minimum bid price deficiency notice
Received Nasdaq notice on Sept 21, 2023 for common stock bid price below $1.00 for 30 consecutive business days.
Cardio Diagnostics extends Yorkville second closing to Dec 2023; lowers floor price to $0.20
Second closing deadline extended to December 29, 2023 from September 15, 2023, subject to conditions.
Stockholders approve issuance of up to 20.4M shares upon conversion of $11.2M debentures to YA II PN
Share issuance could exceed 20% of outstanding common stock and be priced below Nasdaq Minimum Price.
Gross proceeds up to $11.2M from YA II PN, Ltd. (Yorkville); first tranche $5M debenture at 90% ($4.5M), second $6.2M upon SEC reg. effectiveness.
Cardio Diagnostics completes SPAC merger with Mana Capital; begins trading as CDIO, CDIOW
Mana stockholders approved merger on Oct 25; Business Combination closed same day, Legacy Cardio becomes subsidiary.
Mana Capital extends business combo deadline to Oct 26, 2022 with $216,667 loan from Cardio
Second one-month extension from Sept 26 to Oct 26, 2022, with up to 12 extensions permitted.
Cardio Diagnostics secures U.S. patent for cardiovascular disease detection technology
U.S. Patent No. 11,414,704 issued by USPTO to University of Iowa Research Foundation (UIRF), exclusively licensed to Cardio Diagnostics.
Amendment dated September 15, 2022 increases shares reserved under Cardio Diagnostics Holdings 2022 Incentive Plan to 3,265,516.
Mana Capital SPAC to merge with Cardio Diagnostics in deal valuing target at $75M base
Cardio stockholders to receive shares of Mana Capital common stock valued at $10.00/share; base consideration $75M.
Mana Capital Acquisition Corp. closes IPO and private placement, raising $64.5M
IPO of 6.2M units at $10 each generated gross proceeds of $62M.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Allan Liu and Loren Mortman also resigned as members of the Board of Directors, effective as of the Closing.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Effective as of the Closing of the Business Combination, Jonathan Intrater resigned as Chairman of the Board, Chief Executive Officer and Chief Financial Officer of the Company.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
On the date of the Closing, and in accordance with the terms of the Merger Agreement, the Board became comprised of seven directors: Warren Hosseinion, MD, Meeshanthini (Meesha) Dogan, PhD, Robert Philibert, MD PhD, Brandon Sim, Stanley K. Lau, MD, Oded Levy and James Intrater.
Immediately following the consummation of the Business Combination, the following individuals became the executive officers of the Company: Meeshanthini Dogan as Chief Executive Officer; Robert Philibert as Chief Medical Officer; Elisa Luqman as Chief Financial Officer; Timur Dogan as Chief Technology Officer and Khullani Abdullahi as Vice President of Revenue and Strategy.
Max materiality 0.80 · Median 0.55 · Most common event other_material